
Opinion|Videos|October 28, 2024
Integrating Tisotumab Vedotin into Ovarian Cancer Therapy
Panelists discuss the integration of tisotumab vedotin into ovarian cancer therapy, covering its role in treatment approaches, patient selection, adverse event management, clinical pearls, challenges in practice, and the implications of the drug’s payload on treatment efficacy.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Where does tisotumab vedotin fit in your current treatment approach?
- In which patients do you consider this treatment option?
- Adverse event management and clinical pearls
- What challenges do you see in practice with tisotumab vedotin, and how do you approach associated management?
- Payload of tisotumab vedotin
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
4
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
5



































